-
Mashup Score: 0Odronextamab Demonstrates Long-Term High Response Rates for Heavily Pretreated R/R Follicular Lymphoma: ELM-2 - 8 day(s) ago
At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of odronextamab therapy for patients with relapsed/refractory follicular lymphoma with a follow-up of more than 2 years.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet
At the EHA 2025 Congress, Stefano Luminari, MD shared results from the ELM-2 trial which evaluated the efficacy of #odronextamab therapy for patients with relapsed/refractory #FL with a follow-up of more than 2 years. Learn more: https://t.co/SlPTWneGjr https://t.co/n14872PTqq